Entasis, which previously raised $50m in a Novo and AstraZeneca-backed series B last year, has added $31.9m in series B-1 round.
US-based anti-infective treatment developer Entasis Therapeutics yesterday raised $31.9m in a series B-1 extension to close the round, already backed by pharmaceutical firms Novo and AstraZeneca, at $81.9m.
The additional capital was provided by Pivotal BioVenture Partners, Sofinnova Ventures and TPG Biotech.
The original tranche, raised in March 2016, was led by fife sciences-focused investment firm Clarus, with participation from Novo and AstraZeneca as well as specialist investment firm Frazier Healthcare Partners and investment adviser Eventide Funds.
Entasis was spun…
